Other

Amgen Research (Munich) Gmbh

Gsf-Forschungszentrum Fuer Umwelt Und Gesundheit Gmbh

Bavarian Nordic A/s

Gsf-Forschungszentrum Fur Umwelt Und Gesundheit, Gmbh

Micromet Ag

Bavarian Nordic Research Institute Gmbh

Gsf-Forschungszentrum Fur Unwelt Und Gesundheit Gmbh

Robert Saller

Brian Salmons

Walter Henry Günzburg

Carsten Reinhardt

Walter H G&uuml;nzburg

Peter Karle

Matthias Löhr

Walter H Gunzburg

Peter Müller

Peter M&uuml;ller

Matthias L&ouml;hr

Mariana Marin

David Winder

Mireia Pelegrin

Marc Piechaczyk

The present invention relates to the use of an anti-EpCAM antibody for the manufacture of a medicament for the treatment of metastatic breast cancer. The present invention further relates to a method of treating metastatic breast cancer comprising administering said anti-EpCAM antibody.

Treatment of metastatic breast cancer

The present invention relates to a retroviral vector undergoing promoter conversion comprising a 5'LTR region of the structure U3-R-U5; one or more sequences selected from coding and non-coding sequences; and a 3&#x2032;LTR region comprising a completely or partially deleted U3 region wherein said deleted U3 region is replaced by a polylinker sequence, followed by the R and U5 region. The retroviral vector undergoes promoter conversion and is useful as a gene transfer vehicle for targeted gene therapy.

Non self-inactivating, expression targeted retroviral vectors

The present invention relates to retroviral vectors carrying DNA sequences encoding SDI-1, function analogues of SDI-1, or fragments thereof, or antisense SDI-1 DNA sequences, and especially retroviral vectors carrying the SDI-1 or antisense SDI-1 sequences under the transcriptional control of target cell specific regulatory elements or promoters or X-ray inducible promoters. Further, the invention relates to the use of such retroviral vectors for the production of recombinant retroviral particles useful for the treatment of disorders or diseases responsive to the anti-proliferative activity of SDI-1, or the proliferative activity of antisense SDI-1 sequences.

Retroviral vectors carrying senescent cell derived inhibitors 1 (SDI-1)or antisense SDI-1 nucleotide sequences

The present invention relates to recombinant vectors carrying sequences encoding naturally occurring antimicrobial peptides or derivatives thereof for the treatment of mammalian tumours and viral infections such as HIV infections and bacterial and fungal infections. In particular the present invention relates to retroviral vectors. Furthermore, the present invention relates to retroviral vectors which undergo promoter conversion (Procon vectors) carrying such sequences. Since these vectors also carry tumour or virus specific regulatory elements, the therapeutic antimicrobial peptide will be delivered and expressed only in relevant, affected cells and not in innocent bystander cells.

Vectors carrying therapeutic genes encoding antimicrobial peptides for gene therapy

The present invention relates to capsules encapsulating cytochrome P450 producing cells and cytochrome P450 producing retroviral packaging cells. Furthermore, the present invention relates to the treatment of cancer or any other relevant disease with said capsules and to the use of said capsules for the preparation of a pharmaceutical composition for said treatment.

Encapsulated cells producing cytochrome P450

The present invention relates to encapsulated cells producing viral particles, especially retroviral particles containing the genome of a retroviral vector carrying therapeutic genes, to methods for the preparation of such encapsulated cells, as well as to the use of such encapsulated cells for the delivery of genes, especially therapeutic genes, to target organs/cells.

Encapsulated cells producing viral particles

The present invention relates to capsules encapsulating antibody-producing cells, and to use of such capsules and encapsulated cells, respectively, for implantation in vivo for long term delivery or sustained delivery of antibodies of therapeutic interest.

Encapsulated cells producing antibodies

Growing community of inventors

Munich, Germany

Robert Saller